Russian Direct Investment Fund (RDIF) confirms efficacy of over 90% for Sputnik V vaccine.

RDIF reports that a data analysis (n=22,714) conducted 21 days after first dose of vaccine or placebo upon reaching third and final statistically significant representative control point of trial indicated a 91.4% efficacy rate.

Source:

PharmaTimes